Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finotonlimab, Cetuximab, and Docetaxel as Neoadjuvant Therapy for Recurrent HNSCC
NCT07618624Phase 2Enrolling by invitation
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of finotonlimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Sun Yat-sen University. Primary endpoint: Major Pathological Response Rate at 12 weeks. Started Apr 2026; status: enrolling by invitation.
02
Drugs
finotonlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07618624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07618624.